Winklevoss Capital Sells its Zcash Mining Platforms to a Company It Backs and Acquires Shares of That Company

cryptonews.ruPublicado em 2026-08-20Última atualização em 2026-08-20

Resumo

Winklevoss Capital, through its Winklevoss Treasury Investments, has acquired a warrant for approximately 43.3 million shares of Cypherpunk Technologies Inc. (NASDAQ: CYPH) as part of a deal where Cypherpunk purchased a new Zcash mining venture. The transaction, valued at $33.33 million, dilutes existing shareholders and grants the Winklevoss brothers a significant stake in Zcash investments. Cypherpunk Mining, operating Z15 Pro machines with an estimated 18% of the Zcash network's Equihash hashrate, is positioned as the world's largest dedicated Zcash mining fleet, hosted at debt-free, low-cost U.S. facilities. The company aims to increase its ZEC holdings from the current 1.92% of the circulating supply to 5%, using mined coins to fund growth and new privacy technologies. Cameron Winklevoss framed the move as a play to bring Zcash mining dominance to the U.S., contrasting it with the historically foreign-concentrated mining landscape. Cypherpunk, formerly the biotech firm Leap Therapeutics, rebranded after a Winklevoss-led investment round. The announcement follows a period of volatility for Zcash, which faced a significant security flaw in early 2026, causing sharp declines in both ZEC and CYPH share prices before patches were deployed.

Winklevoss Capital received a warrant to acquire approximately 43.3 million company shares as part of Cypherpunk Technologies' purchase of a new Zcash mining enterprise.

This structure dilutes existing shareholders and gives the Gemini founders a larger stake in Zcash investments. Cypherpunk shares trade on Nasdaq under the ticker CYPH.

43,290,042 New Shares Lead to Dilution for Every CYPH Holder

Cypherpunk paid $33.33 million by issuing a pre-paid warrant to Winklevoss Treasury Investments for 43,290,042 common shares exercisable at $0.001 per share. This implies an estimated share price of $0.77 per share.

CYPH shares rose 15.85% on the August 18 session with trading volume roughly 4.2 times the daily average. A similar jump of 15.4% occurred following the May earnings report release.

The Cypherpunk Mining project is launched and operating on Z15 Pro machines. They generate an Equihash hash rate of ~4.2 GSol/s, which the company estimates accounts for about 18% of the total Zcash network.

The fleet is distributed across facilities in the U.S., and Cypherpunk calls it the world's largest Zcash operation. This is a potential market worth over $250 million annually at current $ZEC prices, compared to roughly 43,800 $ZEC in monthly network mining rewards.

The company already holds 323,394.38 $ZEC, about 1.92% of the total circulating cryptocurrency, and expresses a desire to acquire an additional 5%. Chief Investment Officer Will McEvoy stated that the mined coins give the company "financial and operational flexibility to fund future growth, acquire additional $ZEC, and invest in new privacy-enabling technologies."

The company invited Kevin Zhang, a long-time mining operator, to lead the mining operations.

Cameron Winklevoss Describes the Deal as a Play on the U.S. Market

"Zcash was concentrated in the hands of a small number of miners, pools, and ASIC manufacturers, almost all of which were outside the United States," Winklevoss wrote on X after the announcement.

He added that Cypherpunk's fleet is "hosted at facilities in the United States, is fully owned, debt-free, and has low energy costs." He and his brother Tyler presented the launch as a rare opportunity for public market investors to gain exposure to Zcash mining.

The company was originally named Leap Therapeutics, a biotech firm that rebranded as Cypherpunk Technologies in November 2025 following a $58.88 million private placement led by Winklevoss Capital, as Cryptopolitan reported. At that time, its treasury held approximately 203,775 $ZEC purchased at an average price of $245 per coin.

Earlier in 2026, Zcash faced a security issue when Shielded Labs researcher Taylor Hornby discovered a bug in the zero-knowledge scheme of the Orchard pool used by Zcash.

Theoretically, this could have allowed an attacker to create counterfeit $ZEC without detection. At the time, $ZEC prices fell by more than 50%, and Cypherpunk shares plunged by about 40%. Developers released an emergency patch in early June, followed by the Ironwood update in July.

Criptomoedas em alta

Perguntas relacionadas

QWhat did Winklevoss Capital receive as part of the deal with Cypherpunk Technologies regarding the new Zcash mining venture?

AWinklevoss Capital received a warrant to purchase approximately 43.3 million shares of the company.

QWhat is the expected impact of the issuance of 43,290,042 new shares for Cypherpunk (CYPH)?

AThe issuance of the new shares is expected to dilute the stake of each existing CYPH shareholder.

QHow much of the total Zcash network hash rate does Cypherpunk Mining's fleet of Z15 Pro machines estimate to contribute?

ACypherpunk Mining's fleet estimates to contribute about 18% of the total Zcash network's hash rate.

QAccording to Cameron Winklevoss, what makes the Cypherpunk deal a unique opportunity for public market investors?

AHe described it as a rare opportunity for public market investors to gain access to Zcash mining, as the Cypherpunk fleet is US-located, fully owned, debt-free, and has low power costs.

QWhat security issue affected Zcash earlier in 2026, and what was its impact on CYPH stock?

AA bug was found in the zero-knowledge scheme of Zcash's Orchard pool, which theoretically could allow counterfeit ZEC creation. This caused ZEC's price to drop over 50% and CYPH stock to fall roughly 40%.

Leituras Relacionadas

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

On August 19, J.P. Morgan (JPM) published a research report analyzing Moderna's recent Phase III trial success for its Individualized Neoantigen Therapy (INT), developed in partnership with Merck, in adjuvant melanoma. The trial met its primary endpoint of significantly improved recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. While JPM acknowledged the strong clinical value of these results, particularly the prevention of distant metastasis, the bank stated that this success was widely anticipated, with an 85% prior probability of success, and is already reflected in Moderna's current market valuation. Following the announcement, Moderna's stock rose in pre-market trading. However, JPM maintained its Underweight rating and $40 price target, implying approximately 36% downside from the current price of ~$63. The core rationale is that the success in adjuvant melanoma, a relatively small market in immuno-oncology, is fully priced in. Moderna's future valuation hinges entirely on INT's ability to demonstrate similar efficacy across broader cancer indications. JPM's valuation model incorporates only a modest risk-adjusted value (~$3/share) for the melanoma approval. Approximately $15/share of its target price is attributed to INT's potential in other cancer types. The report identifies upcoming data readouts in non-melanoma cancers (e.g., lung, head & neck, renal) as the critical variable that will determine the platform's ultimate value. Upside risks include better-than-expected data in these new indications, while downside risks involve clinical failures, regulatory delays, or commercial underperformance. In conclusion, JPM views the pre-market stock move as driven by short covering and trading sentiment rather than a fundamental re-rating. The bank remains bearish, arguing that Moderna must now prove INT's efficacy as a platform technology beyond melanoma to justify its current market cap.

marsbitHá 27m

JPMorgan Research Report Analysis: Moderna's INT Trial Meets Endpoints, but Market Already Priced In

marsbitHá 27m

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

The article discusses the U.S. Treasury's recent direct intervention to suppress long-term bond yields through buyback operations. While distinct from traditional Yield Curve Control (YCC), this move is interpreted as direct government intervention in its own financing costs. The author emphasizes the short-term tactical nature of this action and contrasts it with the Federal Reserve's upcoming, potentially divergent, policy stance at Jackson Hole. The core issue is framed as a long-term U.S. strategic dilemma: managing high deficit levels. The analysis argues that deficit reduction cannot realistically come from spending cuts or traditional industries, but must rely on achieving higher economic growth driven by technological breakthroughs. Current monetary tightening, while possibly curbing yields and inflation in the short term, is seen as potentially counterproductive to this necessary long-term investment in technology and supply chain resilience. The piece draws historical parallels, placing the current intervention between the 2000-2002 Treasury buybacks (for liquidity) and larger-scale Fed-led "Operation Twist" maneuvers. The effectiveness of the Treasury's action is deemed limited without Federal Reserve cooperation, which would signify a more significant policy shift. Ultimately, the author views such technical, bureaucratic interventions as treating symptoms rather than the underlying disease of the U.S. economy's structural challenges and "K-shaped" divergence. The conclusion suggests that sustained yield suppression by the Fed, combined with specific geopolitical outcomes, could serve as a catalyst for a more profound discussion on broader U.S. and dollar trajectory.

marsbitHá 28m

Treasury Department Directly Intervenes to Suppress Long-Term Interest Rates

marsbitHá 28m

Trading

Spot

Artigos em Destaque

Como comprar COMP

Bem-vindo à HTX.com!Tornámos a compra de Compound (COMP) simples e conveniente.Segue o nosso guia passo a passo para iniciar a tua jornada no mundo das criptos.Passo 1: cria a tua conta HTXUtiliza o teu e-mail ou número de telefone para te inscreveres numa conta gratuita na HTX.Desfruta de um processo de inscrição sem complicações e desbloqueia todas as funcionalidades.Obter a minha contaPasso 2: vai para Comprar Cripto e escolhe o teu método de pagamentoCartão de crédito/débito: usa o teu visa ou mastercard para comprar Compound (COMP) instantaneamente.Saldo: usa os fundos da tua conta HTX para transacionar sem problemas.Terceiros: adicionamos métodos de pagamento populares, como Google Pay e Apple Pay, para aumentar a conveniência.P2P: transaciona diretamente com outros utilizadores na HTX.Mercado de balcão (OTC): oferecemos serviços personalizados e taxas de câmbio competitivas para os traders.Passo 3: armazena teu Compound (COMP)Depois de comprar o teu Compound (COMP), armazena-o na tua conta HTX.Alternativamente, podes enviá-lo para outro lugar através de transferência blockchain ou usá-lo para transacionar outras criptomoedas.Passo 4: transaciona Compound (COMP)Transaciona facilmente Compound (COMP) no mercado à vista da HTX.Acede simplesmente à tua conta, seleciona o teu par de trading, executa as tuas transações e monitoriza em tempo real.Oferecemos uma experiência de fácil utilização tanto para principiantes como para traders experientes.

509 Visualizações TotaisPublicado em {updateTime}Atualizado em 2026.06.02

Como comprar COMP

Discussões

Bem-vindo à Comunidade HTX. Aqui, pode manter-se informado sobre os mais recentes desenvolvimentos da plataforma e obter acesso a análises profissionais de mercado. As opiniões dos utilizadores sobre o preço de COMP (COMP) são apresentadas abaixo.

活动图片